- Published on
KembaraXtra- Medicine – Adrenal Incidentaloma
An adrenal incidentaloma is defined as an adrenal mass measuring ≥1 cm that is discovered unintentionally on imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound performed for reasons unrelated to suspected adrenal disease. This definition excludes patients undergoing adrenal imaging as part of screening for hereditary syndromes or those with known extra-adrenal malignancy undergoing staging or surveillance. With the increasing use of cross-sectional imaging, adrenal incidentalomas are being identified with growing frequency.
Adrenal incidentalomas are found in approximately 1.4% to 3.2% of the adult population, with prevalence increasing with age and reaching about 3.2% in individuals older than 65 years. These lesions are rarely detected in patients younger than 30 years, and when present in this age group, there should be a heightened suspicion for malignancy or hormonally active tumors. The condition affects men and women nearly equally, with a slight predominance in women. Risk factors include Caucasian race, obesity, diabetes mellitus, and hypertension.
Most adrenal incidentalomas are benign and nonfunctioning, with 75% to 80% representing nonfunctioning adrenal cortical adenomas. However, a clinically important minority are hormonally active. Approximately 5% to 14% of incidentalomas secrete excess hormones, most commonly cortisol or aldosterone. Pheochromocytomas account for roughly 1% to 7%, while primary adrenal malignancies or adrenal metastases represent about 4% to 8% of cases. Because of this wide differential, evaluation focuses on determining both hormonal activity and malignant potential.
After discovery, clinical evaluation should emphasize a targeted history and physical examination to identify features of hormone excess or malignancy. Symptoms of hypercortisolism may include weight gain, proximal muscle weakness, easy bruising, and glucose intolerance. Aldosterone-producing tumors may present with hypertension and hypokalemia. Pheochromocytomas may cause episodic headaches, palpitations, diaphoresis, and flushing. Unintentional weight loss, abdominal pain, or rapid tumor growth may suggest malignancy.
Diagnostic evaluation of an adrenal incidentaloma has two primary goals: assessing hormonal function and estimating malignancy risk. All adrenal incidentalomas measuring ≥1 cm should undergo biochemical testing for hormone secretion. Recommended laboratory evaluation includes a low-dose dexamethasone suppression test to assess cortisol autonomy, measurement of 24-hour urinary free cortisol or serum ACTH when indicated, and plasma or urine metanephrines to exclude pheochromocytoma. Hypertensive patients should be evaluated with plasma aldosterone concentration and plasma renin activity to screen for primary aldosteronism. Findings such as hirsutism, virilization, or gynecomastia should prompt evaluation of androgen and estrogen levels.
Imaging characteristics play a critical role in risk stratification. Unenhanced CT scanning is the preferred imaging modality if not already performed. Benign adenomas typically appear small (≤3 cm), homogeneous, and lipid-rich with low attenuation (<10 hounsfield units) and rapid contrast washout. in contrast, adrenocortical carcinoma metastatic lesions are often larger (>4 cm), irregular, heterogeneous, and demonstrate delayed contrast washout. MRI may provide additional information, particularly when CT findings are indeterminate, while PET scanning may be useful in patients with a history of malignancy.
Management depends on tumor size, functionality, growth rate, and patient-specific factors. All hormonally active tumors and masses suspicious for malignancy should be referred for surgical evaluation, typically adrenalectomy. Nonfunctioning tumors larger than 4 to 5 cm carry a significantly increased risk of malignancy and are generally recommended for surgical removal. Smaller nonfunctioning lesions (<3 cm) with benign imaging features can be safely observed.< />pan>
For nonfunctioning incidentalomas managed conservatively, follow-up typically includes repeat imaging at 3 to 6 months, then annually for 1 to 2 years, along with annual hormonal reassessment for up to 5 years. An increase in tumor size greater than 1 cm or development of hormonal activity warrants surgical consultation. If no progression occurs after five years, further follow-up is generally unnecessary, as late hormonal conversion is unlikely.
Overall, most adrenal incidentalomas are benign and nonfunctional, requiring observation rather than intervention. However, careful and systematic evaluation is essential, particularly in younger patients and those with suspicious clinical, biochemical, or imaging features, to avoid missing hormonally active tumors or malignancy.
0 Comments
